BioAtla has presented first-in-human Phase I study data of its anti-cancer therapy, BA3182, targeting those with ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the ...

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) ...

Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

One-time surgical application of genetically engineered autologous keratinocyte sheets provides significant closure and pain ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This situation generates substantial inefficiencies with many scanners being ...